<DOC>
	<DOCNO>NCT00929162</DOCNO>
	<brief_summary>The purpose study compare progression-free survival patient advanced ovarian cancer treat ZD4054 combination carboplatin+paclitaxel versus placebo combination carboplatin+paclitaxel .</brief_summary>
	<brief_title>ZD4054 ( Zibotentan ) Placebo Plus Chemotherapy Patients With Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically proven diagnosis : Epithelial ovarian carcinoma Fallopian tube carcinoma Primary serous peritoneal carcinoma Radiologically document measurable disease accord RECIST criterion assess Computerised Tomography ( CT ) Magnetic Resonance Imaging MRI ) radiologically document nonmeasurable ( evaluable ) disease . Advanced disease amenable curative surgery radiotherapy time study entry evidence disease recurrence progression least 6 month follow treatment cessation firstline platinum contain therapy Clinical evidence central nervous system ( CNS ) metastases Nonepithelial ovarian cancer , include malignant mixed Mullerian tumour mucinous carcinoma peritoneum Tumour borderline malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>ovarian</keyword>
	<keyword>cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>sensitive</keyword>
	<keyword>ZD4054</keyword>
</DOC>